8 completed, 6 recruiting, 4 not yet recruiting, 3 active not recruiting. 13 Phase 1, 7 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 5, Recruiting 4, Not yet recruiting 3, Active not recruiting 1 |
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 2 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Shanghai Minwei Biotechnology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia MWX203, Inclisiran Sodium Injection, Placebo - Mixed Dyslipidemia | Phase 2 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 216 | 2026-09-25 | 2026-09-08 |
| Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity MWN117, Placebo - Healthy Volunteers, Obesity | Phase 1 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 48 | 2026-09-18 | 2026-09-17 |
| Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 3 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 760 | 2026-09-01 | 2026-08-21 |
| Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants MWN110, Placebo - Overweight , Obesity | Phase 1 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 103 | 2026-08-26 | 2026-08-24 |
| Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus MWN109 1, MWN109 2, MWN109 3 - Type 2 Diabetes Mellitus (T2DM) | Phase 2 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 240 | 2026-06-23 | 2026-09-09 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MWX205 MWX205, Placebo - Dyslipidemias | Phase 1 | Not yet recruiting | Shanghai Minwei Biotechnology Co., Ltd | 37 | 2026-06-22 | 2026-06-10 |
| A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese Participants MWN109 Tablets - Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity | Phase 1 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 162 | 2026-05-24 | 2026-09-03 |
| Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity MWN105 1, MWN105 2, MWN105 3 - Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 36 | 2026-04-26 | 2026-09-08 |
| Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension MWX401 1, MWX401 2, MWX401 3 - Essential Hypertension, Healthy Volunteers | Phase 1 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 46 | 2026-03-19 | 2026-09-08 |
| Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity MWN109 1, MWN109 2 - Overweight , Obesity | Phase 2 | Active not recruiting | Shanghai Minwei Biotechnology Co., Ltd | 71 | 2026-03-02 | 2026-09-04 |
| Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 255 | 2026-01-05 | 2026-08-28 |
| Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Active not recruiting | Shanghai Minwei Biotechnology Co., Ltd | 125 | 2025-12-26 | 2026-08-28 |
| Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity MWN105 1, MWN105 2, MWN105 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-09-03 | 2026-09-04 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 2 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 120 | 2025-08-23 | 2026-08-28 |
| Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity MWN109 1, MWN109 2, MWN109 3 - Overweight , Obesity | Phase 1 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 40 | 2025-07-14 | 2026-08-28 |
| Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects MWX203 S1, Placebo, MWX203 S2 - Healthy Volunteers | Phase 1 | Active not recruiting | Shanghai Minwei Biotechnology Co., Ltd | 54 | 2025-07-07 | 2026-09-02 |
| Phase I Clinical Study of MWN109 Tablets in Healthy Chinese Participants MWN109 tablet, Placebo - Healthy Volunteers | Phase 1 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 98 | 2025-06-27 | 2026-08-26 |
| A Study to Evaluate MWN109 Tablets in Healthy Adult Participants MWN109 tablet, Placebo - Overweight or Obesity | Phase 1 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 60 | 2025-06-18 | 2025-11-20 |
| A Study to Evaluate MWN109 Injection in Healthy Subjects Placebo, Subcutaneous single and mutiple dose - Overweight or Obese | Phase 1 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 72 | 2025-03-17 | 2025-04-15 |
| Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers MWN105, Placebo - Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | Shanghai Minwei Biotechnology Co., Ltd | 55 | 2024-12-19 | 2026-09-03 |
Showing 20 of 21. Sign in to see all of them.
Obesity (14) · Overweight (13) · Diabetes Mellitus, Type 2 (4) · Dyslipidemias (1) · Essential Hypertension (1)
semaglutide (1)
China (18) · Australia (2)
Guitao Zhang (1)